Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBOT NASDAQ:PDEX NASDAQ:PSTV NASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBOTMicrobot Medical$2.10-4.3%$2.39$1.60▼$4.67$140.70M1.061.81 million shs631,532 shsPDEXPro-Dex$57.78+2.2%$50.21$23.47▼$61.62$183.30M-0.1225,878 shs4,102 shsPSTVPlus Therapeutics$5.92-2.0%$5.99$2.90▼$23.42$40.61M1.4415,571 shs26,711 shsSTIMNeuronetics$1.40-7.2%$1.49$0.80▼$4.85$97.77M1.132.15 million shs864,205 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBOTMicrobot Medical+2.82%+4.29%-15.44%+6.83%-13.10%PDEXPro-Dex-4.66%+16.85%+9.77%+51.38%+27.59%PSTVPlus Therapeutics-1.31%-0.82%+25.83%-8.17%-63.39%STIMNeuronetics-9.06%-25.50%+11.48%+3.08%-66.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBOTMicrobot Medical$2.10-4.3%$2.39$1.60▼$4.67$140.70M1.061.81 million shs631,532 shsPDEXPro-Dex$57.78+2.2%$50.21$23.47▼$61.62$183.30M-0.1225,878 shs4,102 shsPSTVPlus Therapeutics$5.92-2.0%$5.99$2.90▼$23.42$40.61M1.4415,571 shs26,711 shsSTIMNeuronetics$1.40-7.2%$1.49$0.80▼$4.85$97.77M1.132.15 million shs864,205 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBOTMicrobot Medical+2.82%+4.29%-15.44%+6.83%-13.10%PDEXPro-Dex-4.66%+16.85%+9.77%+51.38%+27.59%PSTVPlus Therapeutics-1.31%-0.82%+25.83%-8.17%-63.39%STIMNeuronetics-9.06%-25.50%+11.48%+3.08%-66.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBOTMicrobot Medical 2.60Moderate Buy$7.50258.00% UpsidePDEXPro-Dex 2.50Moderate Buy$70.0021.15% UpsidePSTVPlus Therapeutics 2.43Hold$58.00879.73% UpsideSTIMNeuronetics 2.00Hold$3.00114.90% UpsideCurrent Analyst Ratings BreakdownLatest PSTV, PDEX, MBOT, and STIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/1/2026PDEXPro-Dex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/21/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/14/2026MBOTMicrobot Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/10/2026MBOTMicrobot Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$475.00 ➝ $65.003/31/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/19/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.003/19/2026STIMNeuronetics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $3.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBOTMicrobot MedicalN/AN/AN/AN/A$1.15 per shareN/APDEXPro-Dex$66.59M2.77$3.06 per share18.90$11.23 per share5.15PSTVPlus Therapeutics$5.21M7.79N/AN/A$0.72 per share8.22STIMNeuronetics$149.16M0.65N/AN/A$0.38 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBOTMicrobot Medical-$13.14M-$0.29N/AN/AN/AN/A-24.44%-23.12%5/13/2026 (Estimated)PDEXPro-Dex$8.98M$3.6215.87N/AN/A16.08%22.78%14.30%7/8/2026 (Estimated)PSTVPlus Therapeutics-$22.39M-$31.00N/AN/AN/A-429.43%N/A-92.28%5/29/2026 (Estimated)STIMNeuronetics-$39M-$0.54N/AN/AN/A-24.48%-139.83%-27.13%N/ALatest PSTV, PDEX, MBOT, and STIM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026PSTVPlus Therapeutics-$0.8480N/AN/AN/A$0.97 millionN/A5/13/2026N/AMBOTMicrobot Medical-$0.08N/AN/AN/A$0.45 millionN/A5/5/2026Q1 2026STIMNeuronetics-$0.17-$0.16+$0.01-$0.16$34.17 million$34.45 million4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million3/27/2026Q4 2025MBOTMicrobot Medical-$0.06-$0.04+$0.02-$0.04$0.11 millionN/A3/17/2026Q4 2025STIMNeuronetics-$0.12-$0.10+$0.02-$0.10$40.84 million$41.78 million3/12/2026Q4 2025PSTVPlus Therapeutics-$0.03$6.25+$6.28N/A$1.23 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMBOTMicrobot MedicalN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBOTMicrobot MedicalN/A23.3323.16PDEXPro-Dex0.323.672.14PSTVPlus TherapeuticsN/A1.231.23STIMNeuronetics3.591.671.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBOTMicrobot Medical16.30%PDEXPro-Dex15.28%PSTVPlus Therapeutics3.28%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipMBOTMicrobot Medical4.74%PDEXPro-Dex45.90%PSTVPlus Therapeutics2.50%STIMNeuronetics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBOTMicrobot Medical2067.16 million63.98 millionOptionablePDEXPro-Dex1403.19 million1.73 millionNot OptionablePSTVPlus Therapeutics206.86 million6.69 millionNot OptionableSTIMNeuronetics18069.59 million63.74 millionOptionablePSTV, PDEX, MBOT, and STIM HeadlinesRecent News About These CompaniesNeuronetics (STIM) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comNeuronetics Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comNeuronetics, Inc. (STIM) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comNeuronetics (NASDAQ:STIM) Announces Earnings Results, Beats Estimates By $0.01 EPSMay 5, 2026 | marketbeat.comNeuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2026 | zacks.comNeuronetics: Q1 Earnings SnapshotMay 5, 2026 | khou.comKNeuronetics Reports First Quarter 2026 Financial and Operating ResultsMay 5, 2026 | globenewswire.comNeuronetics (STIM) to Release Quarterly Earnings on TuesdayMay 3, 2026 | americanbankingnews.comHow The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price TargetMay 2, 2026 | finance.yahoo.comShort Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 16.4%April 30, 2026 | marketbeat.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 29, 2026 | globenewswire.comNeuronetics (STIM) Projected to Post Earnings on TuesdayApril 28, 2026 | marketbeat.comInsider Buying: Neuronetics (NASDAQ:STIM) Major Shareholder Purchases 100,000 Shares of StockApril 23, 2026 | insidertrades.comInsider Buying: Neuronetics (NASDAQ:STIM) Major Shareholder Buys 100,000 Shares of StockApril 22, 2026 | marketbeat.comNeuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference CallApril 21, 2026 | globenewswire.comNeuronetics (NASDAQ:STIM) Stock Rating Upgraded by Wall Street ZenApril 18, 2026 | marketbeat.comNeuronetics (NASDAQ:STIM) Trading Down 2.8% - Here's What HappenedApril 15, 2026 | marketbeat.comNeuronetics (STIM) Receives a Buy from Piper SandlerApril 14, 2026 | theglobeandmail.comNeuronetics Announces CFO Transition and Reaffirms 2026 OutlookApril 14, 2026 | theglobeandmail.comOptum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse PractitionersApril 13, 2026 | globenewswire.comMalvern’s Neuronetics faces sale pressure from top shareholderApril 10, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTV, PDEX, MBOT, and STIM Company DescriptionsMicrobot Medical NASDAQ:MBOT$2.10 -0.10 (-4.34%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Pro-Dex NASDAQ:PDEX$57.78 +1.27 (+2.25%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Plus Therapeutics NASDAQ:PSTV$5.92 -0.12 (-1.99%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Neuronetics NASDAQ:STIM$1.40 -0.11 (-7.24%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
